Epigenomics AG: Voluntary Public Takeover Offer By Summit Hero Holding Not Successful

Berlin, July 12, 2017 – Summit Hero Holding GmbH (“bidder”) announced today that, as of expiry of the extended acceptance period at midnight (24:00 CEST) on July 7, 2017, 62.13 percent of Epigenomics outstanding shares have been tendered under the voluntary public takeover offer or were held by or attributed to the bidder. Consequently, the minimum acceptance threshold of 75.0 percent has not been reached.

Greg Hamilton, CEO of Epigenomics, commented: „It is unfortunate that the takeover offer has not been successful. We now will carefully explore alternative financing options for Epigenomics in order to successfully commercialize our products and develop innovative cancer tests.”

Contact:

Epigenomics AG, Investor Relations, Peter Vogt, Geneststrasse 5, 10829 Berlin, Tel +49 (0) 30 24345 386, Fax +49 (0) 30 24345 555, E-Mail: ir@epigenomics.com

About Epigenomics

Epigenomics is a molecular diagnostics company focused on blood-based detection of cancers using its proprietary DNA methylation biomarker technology. The company develops and commercializes diagnostic products across multiple cancer indications with high medical need. Epigenomics’ lead product, Epi proColon®, is a blood-based screening test for the detection of colorectal cancer. Epi proColon has received approval from the U.S. Food and Drug Administration (FDA) and is currently marketed in the United States, Europe, and China and selected other countries. Epigenomics’ second product, Epi proLung®, is in development as a blood-based test for lung cancer detection.

For more information, please visit www.epigenomics.com.